Research Output per year
Fingerprint Dive into the research topics where Raushan T Kurmasheva is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 2 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output
Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium
Kurmasheva, R. T., Bandyopadhyay, A., Favours, E., Pozo, V. D., Ghilu, S., Phelps, D. A., McGeehan, G. M., Erickson, S. W., Smith, M. A. & Houghton, P. J., Jul 1 2020, In : Pediatric Blood and Cancer. 67, 7, e28284.Research output: Contribution to journal › Article
Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium
Harrison, D. J., Gill, J. D., Roth, M. E., Zhang, W., Teicher, B., Erickson, S., Gatto, G., Kurmasheva, R. T., Houghton, P. J., Smith, M. A., Kolb, E. A. & Gorlick, R., Jun 1 2020, In : Pediatric Blood and Cancer. 67, 6, e28222.Research output: Contribution to journal › Article
Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report
Kolb, E. A., Houghton, P. J., Kurmasheva, R. T., Mosse, Y. P., Maris, J. M., Erickson, S. W., Guo, Y., Teicher, B. A., Smith, M. A. & Gorlick, R., May 1 2020, In : Pediatric Blood and Cancer. 67, 5, e28098.Research output: Contribution to journal › Article
Prospective use of the single-mouse experimental design for the evaluation of PLX038A
Ghilu, S., Li, Q., Fontaine, S. D., Santi, D. V., Kurmasheva, R. T., Zheng, S. & Houghton, P. J., Feb 1 2020, In : Cancer chemotherapy and pharmacology. 85, 2, p. 251-263 13 p.Research output: Contribution to journal › Article
Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models
Lowery, C. D., Dowless, M., Renschler, M., Blosser, W., VanWye, A. B., Stephens, J. R., Iversen, P. W., Lin, A. B., Beckmann, R. P., Krytska, K., Cole, K. A., Maris, J. M., Hawkins, D. S., Rubin, B. P., Kurmasheva, R. T., Houghton, P. J., Gorlick, R., Anders Kolb, E., Kang, M. H., Patrick Reynolds, C. & 4 others, , Apr 1 2019, In : Clinical Cancer Research. 25, 7, p. 2278-2289 12 p.Research output: Contribution to journal › Article
10
Scopus
citations
Press / Media
Preclinical drug development for childhood cancers
Peter J Houghton & Raushan T Kurmasheva
11/28/19
1 item of Media coverage
Press/Media: Press / Media
WIPO PUBLISHES PATENT OF THE BOARD OF REGENTS OF UNIVERSITY OF TEXAS SYSTEM FOR "NANOPARTICLE COMPOSITIONS AND METHODS OF USE OF PARP INHIBITOR FOR TREATMENT OF CANCER" (AMERICAN INVENTORS)
10/31/19
1 item of Media coverage
Press/Media: Press / Media
Innovative genomics and bioinformatics research at the Greehey Institute
Yidong Chen, Manjeet K Rao, Peter J Houghton & Raushan T Kurmasheva
6/18/19
1 item of Media coverage
Press/Media: Press / Media
Epizyme : to Present New Scientific Data on the Role of HMT Inhibitors in Cancer
11/4/15
2 items of Media coverage
Press/Media: Press / Media
Epizyme to Present New Scientific Data on the Role of HMT Inhibitors in Cancer
11/4/15
31 items of Media coverage
Press/Media: Press / Media